Abstract
There has long been a concern that all psychotropics may have adverse cardiac effects including prolongation of the QT interval. The recent expanded use of the atypical antipsychotics has increased these concerns. This is a selective review of the effect of the major classes of psychotropic drugs on the QT interval. The review also includes a review of methadone given the high co-morbidity between major psychiatric disorders and substance use disorders.
Keywords: Acquired LQTS, drug-induced QT syndrome, methadone, psychiatry, psychotropics, QT interval, QT prolongation, sudden cardiac death, cardiometabolic risk, arrhythmogenic, mesoridazine, phenothiazines, hypomagnesemia, epidemiologic, tachyarrhythmias
Current Psychopharmacology
Title: Psychotropics and Methadone in Acquired Long QT Syndrome
Volume: 1
Author(s): Stephan Carlson and Russell Joffe
Affiliation:
Keywords: Acquired LQTS, drug-induced QT syndrome, methadone, psychiatry, psychotropics, QT interval, QT prolongation, sudden cardiac death, cardiometabolic risk, arrhythmogenic, mesoridazine, phenothiazines, hypomagnesemia, epidemiologic, tachyarrhythmias
Abstract: There has long been a concern that all psychotropics may have adverse cardiac effects including prolongation of the QT interval. The recent expanded use of the atypical antipsychotics has increased these concerns. This is a selective review of the effect of the major classes of psychotropic drugs on the QT interval. The review also includes a review of methadone given the high co-morbidity between major psychiatric disorders and substance use disorders.
Export Options
About this article
Cite this article as:
Carlson Stephan and Joffe Russell, Psychotropics and Methadone in Acquired Long QT Syndrome, Current Psychopharmacology 2012; 1 (2) . https://dx.doi.org/10.2174/2211556011201020183
DOI https://dx.doi.org/10.2174/2211556011201020183 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
PD-1 Inhibitors in Neuroprotection: Modulating Neurotransmitter Pathways for Therapy
Programmed cell death protein-1 (PD-1) inhibitors, widely recognized for their role in immunotherapy, have recently emerged as potential neuroprotective agents. Beyond their traditional application in oncology, PD-1 inhibitors influence neuroimmune interactions, impacting neurotransmitter pathways critical for maintaining brain homeostasis. Dysregulation of these pathways is implicated in neurodegenerative and neuropsychiatric disorders, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry Pharmacology and Drug Discovery for T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects:A Meta-Analysis
Current Vascular Pharmacology Direct Oral Anticoagulants use in Patients with Stable Coronary Artery Disease, Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
Current Pharmaceutical Design Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?
Current Alzheimer Research Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease
Current Neuropharmacology Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes
Inflammation & Allergy - Drug Targets (Discontinued) Primary Ciliary Dyskinesia - An Update on the Genetics of Underlying Pathological Mechanisms
Current Respiratory Medicine Reviews Circulating ACE2 in Cardiovascular and Kidney Diseases
Current Medicinal Chemistry Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets In-silico Design and ADMET Studies of Natural Compounds as Inhibitors of Xanthine Oxidase (XO) Enzyme
Current Drug Metabolism Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery